Stock fact sheet · data as of
Impact BioMedical Inc. (IBO): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Blend
Is IBO undervalued?
IBO closed at 3.15 on 16 Oct 2026, more than 30% above the GLS average fair value of 1.37. Only 0 of the 5 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.
The 5 models disagree widely: GLS Growth gives 0.2703 while Graham Growth gives 2.85. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files IBO under Blend.
Nine valuation models for IBO
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 1.62 | -49% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 2.85 | -9% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 1.07 | -66% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 0.2703 | -91% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 1.03 | -67% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.1684 | -105% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: IBO passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.3 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -93.9%, ROE -93.9%, ROA -68.0% - with debt at 0.00 times equity and negative free cash flow.
Impact BioMedical Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -93.9% |
|---|---|---|---|
| GLS Moat | 2.3 / 10 | ROE | -93.9% |
| Debt / equity | 0.00 | ROA | -68.0% |
| Free-cash-flow yield | -1.9% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 13: No options
IBO has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (13 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 29k shares a day on a market cap of $27M, with a beta of 2.73 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 1 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -130% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 3 / 15 | moat 2.3/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 1 / 20 | 29k shares/day, $27M cap, beta 2.73 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for IBO in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Impact BioMedical Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| TVGN Tevogen Bio Holdings Inc. | 6.51 | - | - | 27No options | $27M |
| ATOS Atossa Therapeutics, Inc. | 2.65 | 4.35 | +39% | 45Weak | $26M |
| IGC IGC Pharma, Inc. | 0.2541 | - | - | 32Weak | $26M |
| EDSA Edesa Biotech, Inc. | 2.67 | 2.00 | -33% | 10No options | $26M |
| SER Serina Therapeutics, Inc. | 1.71 | 0.1037 | -1549% | 10No options | $26M |
| ZIVO ZIVO Bioscience, Inc. | 6.51 | 0.5254 | -1139% | 13No options | $25M |
| MCRB Seres Therapeutics, Inc. | 2.53 | - | - | 33Weak | $25M |
| ABVC ABVC BioPharma, Inc. | 0.9325 | - | - | 26Weak | $25M |
| BYSI BeyondSpring Inc. | 0.5819 | 0.1764 | -230% | 15Weak | $24M |
| CVM CEL-SCI Corporation | 1.74 | 0.2128 | -718% | 12No options | $31M |
| IMMP Immutep Limited | 3.21 | - | - | 28Weak | $24M |
| ESLA Estrella Immunopharma, Inc. | 0.5352 | 0.0238 | -2148% | 21No options | $23M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about IBO
Is IBO undervalued right now?
No: at 3.15 the stock trades 130% above the GLS average fair value of 1.37 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of IBO and what does it mean?
IBO has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for IBO?
1.37 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Impact BioMedical Inc. report earnings next?
No upcoming earnings date is recorded for IBO in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does IBO have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on IBO, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.